Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | RXRB | P28702 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23164044 | 1.00 | ACACB (0.50) | ACACBTSHRSMN1; SMN2SRD5A2RXRA | |
| SCHEMBL23163486 | 0.93 | ACACB (0.48) | ACACBSMN1; SMN2PTGESACACAMRGPRX4 | |
| SCHEMBL23163484 | 0.93 | ACACB (0.48) | ACACBSMN1; SMN2PTGESACACAMRGPRX4 | |
| SCHEMBL29705715 | 0.92 | ALDH1A1 (0.48) | ACACBTSHRSMN1; SMN2SRD5A2RXRA | |
| SCHEMBL23164192 | 0.92 | ALDH1A1 (0.48) | ACACBTSHRSMN1; SMN2SRD5A2RXRA | |
| SCHEMBL23164193 | 0.92 | ALDH1A1 (0.48) | ACACBTSHRSMN1; SMN2SRD5A2RXRA | |
| SCHEMBL23163538 | 0.89 | RXRB (0.55) | ACACBSMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL23163540 | 0.89 | RXRB (0.55) | ACACBSMN1; SMN2SRD5A2RXRARXRB | |
| SCHEMBL23164208 | 0.85 | ALOX5 (0.47) | ACACBSMN1; SMN2ACACAMRGPRX4F7 | |
| SCHEMBL23164209 | 0.85 | ALOX5 (0.47) | ACACBSMN1; SMN2ACACAMRGPRX4F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | ACACB 1718/4885TSHR 606/4885SMN1; SMN2 3442/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | ACACB 2579/4885TSHR 960/4885SMN1; SMN2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.